Letter

Human papillomavirus vaccination

Paradox of vaccination in cervical cancer and screening

BMJ 2008; 337 doi: 10.1136/bmj.a1049 (Published 28 July 2008)
Cite this as: BMJ 2008;337:a1049

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Christian A Gericke, professor of public health policy1
  1. 1University of Adelaide, Adelaide, SA 5005, Australia
  1. christian.gericke{at}adelaide.edu.au

    The development of human papillomavirus (HPV) vaccines and their potential for reducing cervical cancer incidence and mortality is generally considered an important step to improve population health worldwide. For countries without well performing cervical cancer screening programmes and lack of treatment options the current epidemiological and economic models seem applicable.

    However, the assumptions underlying published …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular